vs
Ameris Bancorp（ABCB）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
Ameris Bancorp的季度营收约是Ultragenyx Pharmaceutical Inc.的1.5倍（$314.4M vs $207.3M），Ameris Bancorp净利率更高（35.1% vs -62.0%，领先97.2%），Ultragenyx Pharmaceutical Inc.同比增速更快（25.9% vs 10.0%），过去两年Ultragenyx Pharmaceutical Inc.的营收复合增速更高（38.0% vs 2.3%）
Ameris Bancorp是总部位于美国佐治亚州亚特兰大的银行控股企业，旗下子公司Ameris Bank在佐治亚、阿拉巴马、佛罗里达、北卡罗来纳、南卡罗来纳五州运营全服务网点，另在多州设有抵押贷款专属站点，同时面向个人及企业客户提供便捷的线上及移动银行服务。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
ABCB vs RARE — 直观对比
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $314.4M | $207.3M |
| 净利润 | $110.5M | $-128.6M |
| 毛利率 | — | — |
| 营业利润率 | — | -54.7% |
| 净利率 | 35.1% | -62.0% |
| 营收同比 | 10.0% | 25.9% |
| 净利润同比 | — | 3.5% |
| 每股收益（稀释后） | $1.63 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q1 26 | $314.4M | — | ||
| Q4 25 | $307.1M | $207.3M | ||
| Q3 25 | $314.2M | $159.9M | ||
| Q2 25 | $300.7M | $166.5M | ||
| Q1 25 | $285.9M | $139.3M | ||
| Q4 24 | $290.8M | $164.6M | ||
| Q3 24 | $283.8M | $139.5M | ||
| Q2 24 | $300.6M | $147.0M |
| Q1 26 | $110.5M | — | ||
| Q4 25 | $108.4M | $-128.6M | ||
| Q3 25 | $106.0M | $-180.4M | ||
| Q2 25 | $109.8M | $-115.0M | ||
| Q1 25 | $87.9M | $-151.1M | ||
| Q4 24 | $94.4M | $-133.2M | ||
| Q3 24 | $99.2M | $-133.5M | ||
| Q2 24 | $90.8M | $-131.6M |
| Q1 26 | — | — | ||
| Q4 25 | 45.9% | -54.7% | ||
| Q3 25 | 43.6% | -106.9% | ||
| Q2 25 | 47.4% | -64.8% | ||
| Q1 25 | 39.5% | -102.6% | ||
| Q4 24 | 43.3% | -74.3% | ||
| Q3 24 | 44.4% | -94.6% | ||
| Q2 24 | 42.1% | -79.1% |
| Q1 26 | 35.1% | — | ||
| Q4 25 | 44.2% | -62.0% | ||
| Q3 25 | 33.7% | -112.8% | ||
| Q2 25 | 36.5% | -69.0% | ||
| Q1 25 | 30.8% | -108.5% | ||
| Q4 24 | 42.5% | -80.9% | ||
| Q3 24 | 35.0% | -95.7% | ||
| Q2 24 | 30.2% | -89.5% |
| Q1 26 | $1.63 | — | ||
| Q4 25 | $1.59 | $-1.28 | ||
| Q3 25 | $1.54 | $-1.81 | ||
| Q2 25 | $1.60 | $-1.17 | ||
| Q1 25 | $1.27 | $-1.57 | ||
| Q4 24 | $1.35 | $-1.34 | ||
| Q3 24 | $1.44 | $-1.40 | ||
| Q2 24 | $1.32 | $-1.52 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $421.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $4.1B | $-80.0M |
| 总资产 | $28.1B | $1.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q1 26 | — | — | ||
| Q4 25 | — | $421.0M | ||
| Q3 25 | — | $202.5M | ||
| Q2 25 | — | $176.3M | ||
| Q1 25 | — | $127.1M | ||
| Q4 24 | — | $174.0M | ||
| Q3 24 | — | $150.6M | ||
| Q2 24 | — | $480.7M |
| Q1 26 | $4.1B | — | ||
| Q4 25 | $4.1B | $-80.0M | ||
| Q3 25 | $4.0B | $9.2M | ||
| Q2 25 | $3.9B | $151.3M | ||
| Q1 25 | $3.8B | $144.2M | ||
| Q4 24 | $3.8B | $255.0M | ||
| Q3 24 | $3.7B | $346.8M | ||
| Q2 24 | $3.6B | $432.4M |
| Q1 26 | $28.1B | — | ||
| Q4 25 | $27.5B | $1.5B | ||
| Q3 25 | $27.1B | $1.2B | ||
| Q2 25 | $26.7B | $1.3B | ||
| Q1 25 | $26.5B | $1.3B | ||
| Q4 24 | $26.3B | $1.5B | ||
| Q3 24 | $26.4B | $1.5B | ||
| Q2 24 | $26.5B | $1.6B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | — | $-100.8M |
| 自由现金流率自由现金流/营收 | — | -48.6% |
| 资本支出强度资本支出/营收 | — | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-472.0M |
8季度趋势，按日历期对齐
| Q1 26 | — | — | ||
| Q4 25 | $390.2M | $-99.8M | ||
| Q3 25 | $104.9M | $-91.4M | ||
| Q2 25 | $61.4M | $-108.3M | ||
| Q1 25 | $116.9M | $-166.5M | ||
| Q4 24 | $154.2M | $-79.3M | ||
| Q3 24 | $102.2M | $-67.0M | ||
| Q2 24 | $-97.1M | $-77.0M |
| Q1 26 | — | — | ||
| Q4 25 | $369.6M | $-100.8M | ||
| Q3 25 | $100.5M | $-92.7M | ||
| Q2 25 | $53.7M | $-110.7M | ||
| Q1 25 | $114.2M | $-167.8M | ||
| Q4 24 | $140.7M | $-79.5M | ||
| Q3 24 | $99.8M | $-68.6M | ||
| Q2 24 | $-100.3M | $-79.0M |
| Q1 26 | — | — | ||
| Q4 25 | 120.4% | -48.6% | ||
| Q3 25 | 32.0% | -58.0% | ||
| Q2 25 | 17.9% | -66.5% | ||
| Q1 25 | 39.9% | -120.5% | ||
| Q4 24 | 48.4% | -48.3% | ||
| Q3 24 | 35.2% | -49.2% | ||
| Q2 24 | -33.4% | -53.7% |
| Q1 26 | — | — | ||
| Q4 25 | 6.7% | 0.5% | ||
| Q3 25 | 1.4% | 0.8% | ||
| Q2 25 | 2.5% | 1.5% | ||
| Q1 25 | 0.9% | 1.0% | ||
| Q4 24 | 4.6% | 0.1% | ||
| Q3 24 | 0.8% | 1.2% | ||
| Q2 24 | 1.1% | 1.4% |
| Q1 26 | — | — | ||
| Q4 25 | 3.60× | — | ||
| Q3 25 | 0.99× | — | ||
| Q2 25 | 0.56× | — | ||
| Q1 25 | 1.33× | — | ||
| Q4 24 | 1.63× | — | ||
| Q3 24 | 1.03× | — | ||
| Q2 24 | -1.07× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ABCB
暂无分部数据
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
